These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications. Yang X; Guo Z; Liu Y; Si T; Yu H; Li B; Tian W Expert Rev Anticancer Ther; 2014 Jan; 14(1):31-7. PubMed ID: 24308679 [TBL] [Abstract][Full Text] [Related]
10. MRl of prostate cancer antigen expression for diagnosis and immunotherapy. Ren J; Wang F; Wei G; Yang Y; Liu Y; Wei M; Huan Y; Larson AC; Zhang Z PLoS One; 2012; 7(6):e38350. PubMed ID: 22761679 [TBL] [Abstract][Full Text] [Related]
11. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097 [TBL] [Abstract][Full Text] [Related]
12. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
14. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Dubey P; Wu H; Reiter RE; Witte ON Cancer Res; 2001 Apr; 61(8):3256-61. PubMed ID: 11309275 [TBL] [Abstract][Full Text] [Related]
15. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Saffran DC; Raitano AB; Hubert RS; Witte ON; Reiter RE; Jakobovits A Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2658-63. PubMed ID: 11226295 [TBL] [Abstract][Full Text] [Related]
16. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells. Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y Urol Oncol; 2013 Apr; 31(3):343-51. PubMed ID: 21429770 [TBL] [Abstract][Full Text] [Related]
17. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652 [TBL] [Abstract][Full Text] [Related]
18. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells. Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504 [TBL] [Abstract][Full Text] [Related]
19. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice. Zhao Z; He J; Kang R; Zhao S; Liu L; Li F Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693 [TBL] [Abstract][Full Text] [Related]
20. The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer. Xiang Q; Zhu Z; Luo L; Wang J; Liu Y; Deng Y; Zhou M; Zhao Z Biomed Res Int; 2020; 2020():5395312. PubMed ID: 33029516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]